三個皮匠報告
政策庫
new
付費
搜索

諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線-行業數據

諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線
行業深度報告 過單藥或聯合療法方式覆蓋白血病、非霍奇金淋巴瘤（NHL）、多發性骨髓瘤（MM）等領域。奧布替尼是由公司自主研發的新型 BTK 抑制劑，目前針對復發難治的SLL/CLL、MCL 與 MZL 三個適應癥國內均獲批上市；同時，奧布替尼針對一線SLL/CLL已于 2024年 8月提交 NDA。2024年 6月，引進產品坦昔妥單抗針對二三
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?62KB 圖片尺寸：2327*1073
同報告圖片
 / 44
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第1頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第2頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第3頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第4頁
5oqx5q2J77yM5oiR5peg5rOV5o+Q5Y+W5Zu+54mH5Lit55qE5pWw5o2u5bm255Sf5oiQ6KGo5qC844CC
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第5頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第6頁
fCBBTUzmsrvnlpcgfAp8LS0tfAp8IOWPr+S7peiAkOWPl+W8uuWMlueWl0FNTCB8IOS4jeiAkOWPl+W8uuWMlueWl0FNTCB8Cnwg6K+x5a+85rK755aXIHwg6Zi/57OW6IOe6Iu3562J5by65YyW55aX5pa55qGIIHwKfCDlvLrljJbnlpcr6Z225ZCR6I2v54mp77yI57u05aWI5YWL5ouJ44CBRkxUM+aKkeWItuWJguOAgUlESOaKkeWItuWJgu+8iSB8IOS9juW8uuW6puayu+eWl++8muWMlueWl+aIluiAheiBlOWQiOe7tOWliOWFi+aLiSB8CnwgSURIMeeqgeWPmO+8muiJvuS8j+WwvOW4g+WNleiNr+aIluiBlOWQiOmYv+aJjuiDnuiLtyB8CnwgRkxUM+eqgeWPmO+8muWQieeRnuabv+WwvOiBlOWQiOe7tOWliOWFi+aLieaIlumYv+aJjuiDnuiLtyB8Cnwg5bep5Zu65rK755aXIHwg5Lit5aSn5YmC6YeP6Zi/57OW6IOe6Iu3IHwKfCDnu7TlpYjlhYvmi4nogZTlkIjljrvnlLLln7rljJboja/niakgfAp8IOmihOWQjuS4jeiJr+iAheWwveaXqeihjEhTQ1QgfCDnu6fnu63liY3mnJ/nmoTkvY7lvLrluqbmsrvnlpfmlrnmoYggfAp8IOmihOWQjuiJr+WlveaCo+iAhe+8muWPr+S7peaMieeFp+WPr+iAkOWPl+W8uuWMlueWlyB8Cnwg57u05oyB5rK755aXIHwg5Lit6auY5Y2x57uE5oKj6ICF5Y+v55So5Y6755Sy5Z+65YyW6I2v54mpIHwKfCBGTFQzLUlUROmYs+aAp+aCo+iAheWPr+S7pemAieaLqUZMVDPmipHliLbliYIgfAp8IOWkjeWPkemavuayuy/kuoznur/msrvnlpcgfCDpnbblkJHoja/niakr5Y6755Sy5Z+65YyW6I2v54mp77ya5ZCJ55Ge5pu/5bC844CB57Si5ouJ6Z2e5bC844CB6Im+5LyP5bC85biD44CB57u05aWI5YWL5ouJIHwKfCDlvLrljJbnlpfmlrnmoYjjgIHpnZ7lvLrljJbnlpfmlrnmoYjvvIjogZTlkIjnu7TlpYjlhYvmi4nvvIkgfAp8IOWFjeeWq+ayu+eWl++8mkNBUi1U5rK755aX5ZKM5Y+M6Z2254K55oqX5L2T5rK755aXIHwKfCBhbGxvLUhTQ1QgfAoK6LWE5paZ5p2l5rqQ77ya44CK5oiQ5Lq65oCl5oCn6auT57O755m96KGA55eF77yI6Z2e5oCl5oCn5pep5bm857KS57uG6IOe55m96KGA55eF77yJ5Lit5Zu96K+K55aX5oyH5Y2X77yIMjAyM+W5tOeJiO+8ieOAi+OAgeW8gOa6kOivgeWIuOeglOeptuaJgA==
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第7頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第8頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第9頁
fCDlubTku70gfCDlhajnkINETEJDTOaCo+iAheaVsOmHjyB8IOS4reWbvURMQkNM5oKj6ICF5pWw6YePIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS18CnwgMjAxNiB8IDg1ICAgICAgICAgICAgICAgIHwgMTUgICAgICAgICAgICAgICAgfAp8IDIwMTcgfCA4OCAgICAgICAgICAgICAgICB8IDE2ICAgICAgICAgICAgICAgIHwKfCAyMDE4IHwgOTAgICAgICAgICAgICAgICAgfCAxNyAgICAgICAgICAgICAgICB8CnwgMjAxOSB8IDkzICAgICAgICAgICAgICAgIHwgMTggICAgICAgICAgICAgICAgfAp8IDIwMjAgfCA5NiAgICAgICAgICAgICAgICB8IDE5ICAgICAgICAgICAgICAgIHwKfCAyMDIxRXwgOTkgICAgICAgICAgICAgICAgfCAyMCAgICAgICAgICAgICAgICB8CnwgMjAyMkV8IDEwMiAgICAgICAgICAgICAgIHwgMjEgICAgICAgICAgICAgICAgfAp8IDIwMjNFfCAxMDUgICAgICAgICAgICAgICB8IDIyICAgICAgICAgICAgICAgIHwKfCAyMDI0RXwgMTA4ICAgICAgICAgICAgICAgfCAyMyAgICAgICAgICAgICAgICB8CnwgMjAyNUV8IDExMSAgICAgICAgICAgICAgIHwgMjQgICAgICAgICAgICAgICAgfAp8IDIwMjZFfCAxMTQgICAgICAgICAgICAgICB8IDI1ICAgICAgICAgICAgICAgIHwKfCAyMDI3RXwgMTE3ICAgICAgICAgICAgICAgfCAyNiAgICAgICAgICAgICAgICB8CnwgMjAyOEV8IDEyMCAgICAgICAgICAgICAgIHwgMjcgICAgICAgICAgICAgICAgfAp8IDIwMjlFfCAxMjMgICAgICAgICAgICAgICB8IDI4ICAgICAgICAgICAgICAgIHwKfCAyMDMwRXwgMTI2ICAgICAgICAgICAgICAgfCAyOSAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpGcm9zdCAmIFN1bGxpdmFu44CB6K+66K+a5YGl5Y2O5oub6IKh6K+05piO5Lmm44CB5byA5rqQ6K+B5Yi456CU56m25omA
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第10頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第11頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第12頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第13頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第14頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第15頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第16頁
fCDlubTku70gfCDokKXkuJrmlLblhaXvvIjnmb7kuIflhYPvvIkgfCB5b3kgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tfAp8IDIwMTkgfCAxMDAgICAgICAgICAgICAgICB8IC0gICAgfAp8IDIwMjAgfCA1MCAgICAgICAgICAgICAgICB8IC0gICAgfAp8IDIwMjEgfCAyMDAgICAgICAgICAgICAgICB8IC0gICAgfAp8IDIwMjIgfCAzMDAgICAgICAgICAgICAgICB8IDUwMCUgfAp8IDIwMjMgfCAyMDAgICAgICAgICAgICAgICB8IC0zMDAlfAp8IDIwMjRIMXwgODAwICAgICAgICAgICAgICAgfCA3MDAlIHwKCui1hOaWmeadpea6kO+8mldpbmTjgIHlvIDmupDor4HliLjnoJTnqbbmiYA=
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第17頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第18頁
fCDlubTku70gfCDokKXkuJrmlLblhaXvvIjnmb7kuIflhYPvvIkgfCB5b3kgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS18CnwgMjAxOSB8IDIwMCAgICAgICAgICAgICAgfCAwJSAgIHwKfCAyMDIwIHwgMTAwICAgICAgICAgICAgICB8IDAlICAgfAp8IDIwMjEgfCAxMDAwICAgICAgICAgICAgIHwgOTAwJSB8CnwgMjAyMiB8IDYwMCAgICAgICAgICAgICAgfCA0MCUgIHwKfCAyMDIzIHwgNzAwICAgICAgICAgICAgICB8IDIwJSAgfAp8IDIwMjRRMS0zIHwgNzAwICAgICAgICAgICAgICB8IDAlICAgfAoK6LWE5paZ5p2l5rqQ77yaV2luZOOAgeW8gOa6kOivgeWIuOeglOeptuaJgA==
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第19頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第20頁
fCDlubTku70gfCDnoJTlj5HmipXlhaXvvIjnmb7kuIflhYPvvIkgfCB5b3kgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS18CnwgMjAxOSB8IDEwMC4wMCAgICAgICAgICAgfCAtICAgIHwKfCAyMDIwIHwgMjAwLjAwICAgICAgICAgICB8IC0gICAgfAp8IDIwMjEgfCAzMDAuMDAgICAgICAgICAgIHwgLSAgICB8CnwgMjAyMiB8IDQwMC4wMCAgICAgICAgICAgfCAtICAgIHwKfCAyMDIzIHwgNjAwLjAwICAgICAgICAgICB8IC0gICAgfAp8IDIwMjRRMS0zIHwgNTAwLjAwIHwgLSB8CgrotYTmlpnmnaXmupDvvJpXaW5k44CB5byA5rqQ6K+B5Yi456CU56m25omA
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第21頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第22頁
fCDlubTku70gfCDnoJTlj5HmipXlhaXvvIjnmb7kuIflhYPvvIkgfCB5b3kgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS18CnwgMjAxOSB8IDEwMC4wMCAgICAgICAgICAgfCAtICAgIHwKfCAyMDIwIHwgMTUwLjAwICAgICAgICAgICB8IC0gICAgfAp8IDIwMjEgfCAzMDAuMDAgICAgICAgICAgIHwgLSAgICB8CnwgMjAyMiB8IDUwMC4wMCAgICAgICAgICAgfCAtICAgIHwKfCAyMDIzIHwgNjAwLjAwICAgICAgICAgICB8IC0gICAgfAp8IDIwMjRIMSB8IDMwMC4wMCAgICAgICAgICAgfCAtICAgIHwKCui1hOaWmeadpea6kO+8mldpbmTjgIHlvIDmupDor4HliLjnoJTnqbbmiYA=
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第23頁
PHxvYnNlcnZhdGlvbnw+
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第24頁
fCDlubTku70gIHwg546w6YeR5Y+K562J5Lu354mp77yI55m+5LiH5YWD77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfAp8IDIwMTkgfCA1MDAgICAgICAgICAgICB8CnwgMjAyMCB8IDQwMCAgICAgICAgICAgIHwKfCAyMDIxIHwgMzUwMCAgICAgICAgICAgfAp8IDIwMjIgfCAzMjAwICAgICAgICAgICB8CnwgMjAyMyB8IDI3MDAgICAgICAgICAgIHwKfCAyMDI0SDEgfCAyNTAwICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpXaW5k44CB5byA5rqQ6K+B5Yi456CU56m25omA
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第25頁
fCDlubTku70gfCDokKXkuJrmlLblhaXvvIjnmb7kuIflhYPvvIkgfCB5b3kgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS18CnwgMjAxOSB8IDUsMDAwICAgICAgICAgICAgfCAtNTAlIHwKfCAyMDIwIHwgMiwwMDAgICAgICAgICAgICB8IC02MCUgfAp8IDIwMjEgfCAxMCwwMDAgICAgICAgICAgIHwgNDAwJSB8CnwgMjAyMiB8IDgsMDAwICAgICAgICAgICAgfCAtMjAlIHwKfCAyMDIzIHwgMTgsMDAwICAgICAgICAgICB8IDEyNSUgfAp8IDIwMjRRMS0zIHwgMjAsMDAwIHwgMTAwJSB8CgrotYTmlpnmnaXmupDvvJpXaW5k44CB5byA5rqQ6K+B5Yi456CU56m25omA
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第26頁
fCDlubTku70gfCDnoJTlj5HmipXlhaXvvIjnmb7kuIflhYPvvIkgfCB5b3kgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS18CnwgMjAxOSB8IDYwMDAgICAgICAgICAgICAgfCAtICAgIHwKfCAyMDIwIHwgODAwMCAgICAgICAgICAgICB8IDMzLjMlfAp8IDIwMjEgfCAxMDAwMCAgICAgICAgICAgIHwgMjUlICB8CnwgMjAyMiB8IDExMDAwICAgICAgICAgICAgfCAxMCUgIHwKfCAyMDIzIHwgMTIwMDAgICAgICAgICAgICB8IDkuMSUgfAp8IDIwMjRRMS0zIHwgMTAwMDAgICAgICAgICAgfCAxNy4yJXwKCui1hOaWmeadpea6kO+8mldpbmTjgIHlvIDmupDor4HliLjnoJTnqbbmiYA=
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第27頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第28頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第29頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第30頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第31頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第32頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第33頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第34頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第35頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第36頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第37頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第38頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第39頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第40頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第41頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第42頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第43頁
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第44頁
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
諾誠健華以奧布替尼為核心，已布局具備高度差異化競爭優勢及協同效應的血液瘤在研管線_第45頁
所屬報告： 醫藥生物行業深度報告：血液瘤創新技術層出各亞型均有孵化“重磅炸彈”藥物潛力-241224（52頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站